Your browser doesn't support javascript.
loading
Gain Fat-Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis.
Ishay-Ronen, Dana; Diepenbruck, Maren; Kalathur, Ravi Kiran Reddy; Sugiyama, Nami; Tiede, Stefanie; Ivanek, Robert; Bantug, Glenn; Morini, Marco Francesco; Wang, Junrong; Hess, Christoph; Christofori, Gerhard.
Affiliation
  • Ishay-Ronen D; Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland. Electronic address: pandanaro@gmail.com.
  • Diepenbruck M; Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland.
  • Kalathur RKR; Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland.
  • Sugiyama N; Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland.
  • Tiede S; Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland.
  • Ivanek R; Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland.
  • Bantug G; University Hospital Basel, Department of Biomedicine, University of Basel, Switzerland.
  • Morini MF; Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland.
  • Wang J; Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland.
  • Hess C; University Hospital Basel, Department of Biomedicine, University of Basel, Switzerland.
  • Christofori G; Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland. Electronic address: gerhard.christofori@unibas.ch.
Cancer Cell ; 35(1): 17-32.e6, 2019 01 14.
Article in En | MEDLINE | ID: mdl-30645973
ABSTRACT
Cancer cell plasticity facilitates the development of therapy resistance and malignant progression. De-differentiation processes, such as an epithelial-mesenchymal transition (EMT), are known to enhance cellular plasticity. Here, we demonstrate that cancer cell plasticity can be exploited therapeutically by forcing the trans-differentiation of EMT-derived breast cancer cells into post-mitotic and functional adipocytes. Delineation of the molecular pathways underlying such trans-differentiation has motivated a combination therapy with MEK inhibitors and the anti-diabetic drug Rosiglitazone in various mouse models of murine and human breast cancer in vivo. This combination therapy provokes the conversion of invasive and disseminating cancer cells into post-mitotic adipocytes leading to the repression of primary tumor invasion and metastasis formation.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Flavonoids / Breast Neoplasms / Adipocytes / Cell Transdifferentiation / Rosiglitazone / Neoplasm Metastasis Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2019 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Flavonoids / Breast Neoplasms / Adipocytes / Cell Transdifferentiation / Rosiglitazone / Neoplasm Metastasis Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2019 Document type: Article